Article
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Feb 2009
Okabe Takafumi, Okamoto Isamu, Tsukioka Sayaka, Uchida Junji, Hatashita Erina, Yamada Yuki, Yoshida Takeshi, Nishio Kazuto, Fukuoka Masahiro, Jänne Pasi A, Nakagawa Kazuhiko
Abstract excerpt
PURPOSE: Most non-small cell lung cancer (NSCLC) tumors with activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (EGFR-TKI) such as gefitinib and erlotinib, but they almost invariably develop resistance to these drugs. A secondary mutation in EGFR (T790M) and amplification of the MET proto-oncogene have been identified as mechanisms of...
Topics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Non-Small-Cell Lung
- Drug Combinations
- Drug Resistance, Neoplasm
- Drug Screening Assays, Antitumor
- E2F1 Transcription Factor
- ErbB Receptors